Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled time : 07:00 save search
United States Food & Drug Administration Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease
Published: 2024-03-26 (Crawled : 07:00) - biospace.com/
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 23.18%
H: 0.0%
C: 0.0%
drug disease children food trial submission
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
Published: 2024-03-05 (Crawled : 07:00) - globenewswire.com
NIPNF | $68.91 -52.94% 120
|
Technology Services
| Email alert
Add to watchlist
tg4050 vaccine cancer collaboration trial
Nicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus Resources on NCX 470 Pivotal Trial
Published: 2024-02-28 (Crawled : 07:00) - globenewswire.com
BLK | News | $747.3 -0.86% 0.06% 610K
|
Finance
|
| O: -0.22%
H: 1.8%
C: 1.36%
trial
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Published: 2024-02-26 (Crawled : 07:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
pharma liver disease fibrosis trial results
Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
Published: 2024-01-08 (Crawled : 07:00) - globenewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.89%
H: 0.12%
C: -0.17%
scemblix leukemia trial response molecular
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
Published: 2023-12-21 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
program trial sanofi
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
Published: 2023-12-07 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.19%
H: 0.0%
C: 0.0%
sarclisa free trial
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
Published: 2023-07-28 (Crawled : 07:00) - globenewswire.com
GNTA | $3.745 24.83% 19.89% 4.4K
|
n/a
|
| O: 6.29%
H: 0.0%
C: -11.84%
ongoing expansion tumor trial
Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
Published: 2023-07-13 (Crawled : 07:00) - prnewswire.com
CALT | News | $18.3 -2.35% -2.4% 6.1K
|
Health Technology
|
| O: -1.02%
H: 2.0%
C: 0.24%
cancer trial phase 2
Sagimet Biosciences Presents Positive Phase 2b FASCINATE-2 Clinical Trial Interim Data for Denifanstat for the Treatment of NASH at EASL Congress 2023
Published: 2023-06-23 (Crawled : 07:00) - globenewswire.com
SGMT | $3.97 -2.46% -2.52% 340K
|
Health Technology
| Email alert
Add to watchlist
positive treatment trial nash
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
Published: 2023-06-09 (Crawled : 07:00) - globenewswire.com
EDIT | $5.56 -0.89% -0.9% 1.7M
|
Health Technology
|
| O: 3.75%
H: 1.71%
C: -2.91%
edit-301 positive trial
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight
Published: 2023-05-10 (Crawled : 07:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
obesity pharma trial living
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
Published: 2023-04-10 (Crawled : 07:00) - globenewswire.com
VRNA | $16.1 -1.83% -1.86% 490K
|
Health Technology
|
| O: -0.29%
H: 2.3%
C: 1.71%
pharma copd trial china
Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib
Published: 2023-03-09 (Crawled : 07:00) - prnewswire.com
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 0.36%
H: 0.14%
C: -0.99%
topline trial results
Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis
Published: 2023-02-16 (Crawled : 07:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -1.2%
H: 0.58%
C: -1.49%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.11%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.16%
H: 0.29%
C: -1.56%
il23 trial psoriasis
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease
Published: 2023-01-20 (Crawled : 07:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K
|
Health Technology
|
| O: -1.43%
H: 0.0%
C: 0.0%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -0.07%
H: 1.33%
C: 1.26%
at845 treatment fda disease lifted trial
Video: FSD Pharma submitted a Clinical Trial Application for a planed Phase-1 clinical trial for LUCID-MS
Published: 2023-01-20 (Crawled : 07:00) - fsdpharma.com
HUGE | $0.6167 1.22% 29K
|
Process Industries
|
| O: 0.0%
H: 3.15%
C: -1.59%
pharma application trial lucid-ms phase 1
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
Published: 2022-12-27 (Crawled : 07:00) - globenewswire.com
NBTX | $5.34 -0.74% -0.75% 28K
|
Manufacturing
| Email alert
Add to watchlist
global trial cancer
Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, the Group has recently...
Published: 2022-12-19 (Crawled : 07:00) - biospace.com/
MDGL | $222.18 -2.7% -2.8% 270K
|
Health Technology
|
| O: 219.37%
H: 0.0%
C: 0.0%
rec610 vaccine technology trial approval group
Molecular Partners Presents Positive Interim Safety and Mechanistic Data From Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors
Published: 2022-11-10 (Crawled : 07:00) - globenewswire.com
MOLN | $3.67 -3.42% -3.54% 320
|
Professional, Scientific, and T...
|
| O: 2.15%
H: 1.7%
C: -3.16%
mp0317 treatment ongoing trial tumors positive molecular phase 1
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.